Showing results (31-40 of 354) with videos related to
Sort By:
Pageof 36
Seminars in Oncology|September 1, 1986
Rationale for chemotherapy for patients with advanced non-small-cell lung cancerF A GrecoCancer Biotherapy & Radiopharmaceuticals|May 10, 2000
Phase I study of CBT-1 and Taxol in patients with Taxol resistant cancersR K Oldham, W K Reid, D BarnettCancer Biotherapy & Radiopharmaceuticals|August 1, 1997
The Cancer Biotherapy Research Group [CBRG], formerly the National Biotherapy Study Group [NBSG]: a 10-year perspectiveR O Dillman, R Crispin, R K OldhamBehring Institute Mitteilungen|May 1, 1984
The NCI preclinical screen of biological response modifiersJ E Talmadge, I J Fidler, R K OldhamCancer Research|March 15, 1990
Generation of human lymphokine-activated killer cells following brief exposure to high dose interleukin 2S A Horton, R K Oldham, J R YannelliCancer Biotherapy & Radiopharmaceuticals|October 21, 2000
Growth of tumor-derived activated T cells for the treatment of advanced cancerW M Lewko, P B Hall, R K OldhamJournal of Biological Response Modifiers|January 1, 1984
Practical considerations for the establishment of a screening procedure for the assessment of biological response modifiersJ E Talmadge, R K Oldham, I J FidlerCancer Research|December 1, 1977
Natural cytotoxic reactivity of rat lymphocytes against gross virus-induced tumor cell lines as measured by [125I]iododeoxyuridine and tritiated proline microcytotoxicity assaysR K Oldham, J R Ortaldo, R B HerbermanOncology (Williston Park, N.Y.)|May 29, 2000
Management of patients with cancer of unknown primary siteJ D Hainsworth, F A GrecoPageof 36